<qa>  What is the name of the study that will evaluate the safety and efficacy of combination treatmentThis Phase 12 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab MK-3475 in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. KEYNOTE-162 